{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:25:22Z","timestamp":1774340722358,"version":"3.50.1"},"reference-count":42,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T00:00:00Z","timestamp":1485475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two simple, selective, precise and highly sensitive high\u2010performance thin\u2010layer chromatography (HPTLC) methods have been developed and validated for analysis of five angiotensin II receptor antagonists, namely losartan, irbesartan valsartan, candesartan and olmesartan, which are widely used in clinical practice. HPTLC of the drugs was performed on pre\u2010coated silica gel HPTLC plates 60 F<jats:sub>254<\/jats:sub> by development using a mobile phase composed of chloroform\u2013acetone\u2013glacial acetic acid (7.8:1.5:0.7m v\/v\/v), which was suitable for all of the studied drugs. The first method depended on utilizing reflectance\/fluorescence mode for detection while the second method depended on using 2,3,5,6\u2010tetrachloro\u20101,4\u2010benzoquinone as spraying reagent for the first time to form orange spots scanned at 460 nm. A good linear relationship was obtained over the concentration ranges of 1.2\u201360 and 360\u20133000 ng\/band while detection and quantification limits were in the ranges of 0.07\u20130.43, 45.2\u2013140.49 and 0.21\u20131.29, 137.05\u2013425.74 ng\/band for reflectance\/fluorescence and reflectance\/absorbance methods respectively. The developed methods were applied successfully for their determination in tablets and spiked human plasma for reflectance\/fluorescence method with good accuracy and precision, and so can be applied in the pharmacokinetic and bioavailability studies.<\/jats:p>","DOI":"10.1002\/bmc.3916","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T15:24:34Z","timestamp":1481383474000},"source":"Crossref","is-referenced-by-count":11,"title":["Two selective HPTLC methods for determination of some angiotensin II receptor antagonists in tablets and biological fluids"],"prefix":"10.1002","volume":"31","author":[{"given":"Gamal A.","family":"Salah","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy Assiut University  Assiut Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanaa M.","family":"Abd El\u2010Wadood","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy Assiut University  Assiut Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Khairy","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Science Sohag University  Sohag Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Khorshed","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy Assiut University  Assiut Egypt"},{"name":"Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy Sohag University  Sohag Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2006.06.015"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(02)00073-0"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2007.06.007"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1154"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(98)90308-9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)10365-9"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-9140(01)00379-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(01)00413-7"},{"issue":"2","key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0022-3565(25)38210-8","article-title":"Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist","volume":"265","author":"Cazaubon C.","year":"1993","journal-title":"Journal of Pharmacology and Experimental Therapy"},{"issue":"6","key":"e_1_2_6_11_1","first-page":"419","article-title":"Determination of olmesartan medoxomil in tablets by UV\u2013Vis spectrophotometry","volume":"62","author":"Celebier M.","year":"2007","journal-title":"Pharmazie"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3707"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00507-2"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2005.06.023"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3033"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2011.10.005"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1556\/AChrom.25.2013.1.4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(00)00434-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(01)01496-0"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(01)01496-0"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(01)01496-0"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.4152\/pea.200804315"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(02)01247-5"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(02)01832-0"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1556\/jpc.27.2014.3.8"},{"key":"e_1_2_6_26_1","volume-title":"Harmonised Tripartite Guideline: Validation of AnalyticalProcedures: Text and Methodology Q2 (R1)","author":"ICH","year":"2005"},{"issue":"7","key":"e_1_2_6_27_1","first-page":"S3","article-title":"Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues","volume":"15","author":"Johnston C. I.","year":"1997","journal-title":"Journal of Hypertension Supplements"},{"key":"e_1_2_6_28_1","first-page":"260","article-title":"Quantative analysis of valsartan and hydrochlorothiazide in tablets by high performance thin layer chromatography with ultraviolet absorbtion densitometry","volume":"18","author":"Kadam R. M.","year":"2007","journal-title":"Acta Chromatographica"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.2784"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3141"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3536"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1556\/JPC.24.2011.1.6"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10812-011-9414-0"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2012.07.060"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1599"},{"key":"e_1_2_6_36_1","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.chroma.2011.01.059","article-title":"Validation of thin layer and high performance thin layer chromatographic methods","volume":"1218","author":"Renger B.","year":"2011","journal-title":"Journal of Chromatography A"},{"issue":"6","key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/jaoac\/84.6.1715","article-title":"Simultaneous determination of losartan and hydrochlorothiazide in combined dosage forms by first\u2010derivative spectroscopy and high\u2010performance thin\u2010layer chromatography","volume":"84","author":"Shah S. A.","year":"2001","journal-title":"Journal of AOAC International"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.4103\/0250-474X.33150"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.10.023"},{"key":"e_1_2_6_40_1","first-page":"1261","volume-title":"The National Formulary","author":"United States Pharmacopeia","year":"2008"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(99)01253-4"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262090-00005"},{"key":"e_1_2_6_43_1","first-page":"151","article-title":"Guidelines Subcomittee of the World Health Organization, International Society of Hypertension","author":"World Health Organization","year":"1999","journal-title":"Hypertension Research"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.3916","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.3916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:54:31Z","timestamp":1760036071000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.3916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,27]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/bmc.3916"],"URL":"https:\/\/doi.org\/10.1002\/bmc.3916","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,27]]},"article-number":"e3916"}}